Amgen’s Blincyto gets approval in Japan
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Read More →Demand increasing for tri-county processed food exports
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Read More →Amgen seeks to market osteoporosis drug in Japan
Thousand Oaks biotech giant Amgen is seeking marketing approval in Japan for osteoporosis drug romosozumab, the company announced on Dec. 20. Amgen submitted the request to the Pharmaceuticals and Medical Devices Agency in Japan, where an estimated 12 million people have a high risk of bone fracture. The company is co-developing the drug worldwide with Euronext Read More →
Read More →Embracing trade does not make you a traitor
By Gerhard Apfelthaler On a recent trip to Iran, I couldn’t help but notice the difference in the public narrative regarding the lifting of the sanctions against Iran. While many people in the United States — at least according to mainstream media — seem to think that they got the short end of the stick, Read More →
Read More →Amgen partnering with Japanese company to develop biosimilars
Thousand Oaks-based biotech giant Amgen said July 13 it will partner with a Japanese company to develop and commercialize biosimilars in Japan. Under the partnership, Amgen will develop and manufacture biosimilars while Daiichi Sankyo will obtain marketing approval, distribution and commercialization rights in Japan for the products. The deal also includes several late-stage development drugs. Read More →
Read More →China finds out the hard way that it isn’t easy to knock off No. 1
China’s sudden move to devalue its currency earlier this month has caused a lot of hand-wringing and cost hedge funds a ton of money. But it also teaches a lesson that often is learned painfully — it’s easy to lose your way when you try to be No. 1. That’s why I think the yuan Read More →
Read More →
Sponsored content:
2015-2016 Giving Guide
